Sunday, May 17, 2026

In response to #WHO's declaration of #Ebola #outbreak as a #PHEIC, the #Taiwan CDC has raised its travel advisory for #DRC and #Uganda to Level 2 Alert (May 17 '26)

 


    The Centers for Disease Control (CDC) announced today (May 17) that the World Health Organization (WHO) officially declared the Ebola virus outbreak in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, indicating the risk of cross-border spread and its significant international public health importance.

    According to the latest WHO information, the outbreak is currently mainly occurring in the DRC and has already spread to Uganda

    The WHO points out that the outbreak is caused by the Bundibugyo ebolavirus

    Because there is currently no treatment or vaccine for this virus, and some cases have entered urban areas, epidemic prevention and control face a high challenge. 

    The WHO currently assesses the regional risk as "high" and the global risk as "low."

    The Taiwan Centers for Disease Control (CDC) announced that, based on risk assessments conducted by the WHO and other international sources, it has adjusted the international travel advisory level for the Democratic Republic of Congo and Uganda from Level 1 "Watch" to Level 2 "Alert."

    The CDC stated that while the overall threat posed by this outbreak to Taiwan remains low, considering international travel and global transportation convenience, the possibility of imported cases cannot be completely ruled out. 

    Therefore, the CDC will continue to strengthen border monitoring, medical reporting, and epidemic prevention preparedness.

    The CDC reminds the public that those traveling to the Democratic Republic of Congo, Uganda, and surrounding affected areas should take enhanced protective measures. 

    The CDC also noted that the Ebola virus has an incubation period of up to 21 days

    Upon returning to Taiwan, individuals should undergo 21 days of self-health management. 

    If symptoms such as fever, fatigue, muscle aches, vomiting, diarrhea, or bleeding occur, individuals should wear a mask, seek medical attention immediately, and proactively disclose their travel and contact history. 

    If necessary, individuals can call the 1922 epidemic prevention hotline for assistance from the CDC's regional control centers in conjunction with local health bureaus for subsequent medical treatment and epidemic prevention measures.

    The Centers for Disease Control (CDC) emphasized that it will continue to closely monitor the epidemic information from the WHO and various countries, and adjust epidemic prevention measures as needed to safeguard the health and safety of the people.

Source: 


Link: https://www.cdc.gov.tw/Bulletin/Detail/xBPWe8i0QAsDSdgYUXfp8Q?typeid=9

____

#Epidemic of #Ebola Disease caused by #Bundibugyo virus in #DRC and #Uganda determined a #PHEIC (WHO, May 17 '26)

 


    Pursuant to paragraph 2 of Article 12 - Determination of a public health emergency of international concern, including a pandemic emergency of the International Health Regulations (2005) (IHR), the Director-General of the World Health Organization (WHO), after having consulted the States Parties where the event is known to be currently occurring, is hereby determining that the Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a public health emergency of international concern (PHEIC), but does not meet the criteria of pandemic emergency, as defined in the IHR.

    The Director-General of WHO expresses his gratitude to the leadership of the Democratic Republic of the Congo and Uganda for their commitment to take necessary and vigorous actions to bring the event under control, as well as for their frankness in assessing the risk posed by this event to other States Parties, hence allowing the global community to take necessary preparedness actions.

    In his determination the Director-General of WHO has considered, inter alia, information provided by the States Parties – the Democratic Republic of the Congo and Uganda – scientific principles as well as the available scientific evidence and other relevant information; and assessed the risk to human health, the risk of international spread of disease and of the risk of interference with international traffic.

    The Director-General of WHO considers that the event meets the criteria of the definition of PHEIC, contained in Article 1 - Definitions of the IHR, for the following reasons:


1. The event is extraordinary for the following reasons:

    ° As of 16 May 2026, eight laboratory-confirmed cases, 246 suspected cases and 80 suspected deaths have been reported in Ituri Province of the Democratic Republic of the Congo across at least three health zones, including Bunia, Rwampara and Mongbwalu

    ° In addition, two laboratory confirmed cases (including one death) with no apparent link to each other have been reported in Kampala, Uganda, within 24 hours of each other, on 15 and 16 May 2026, among two individuals travelling from the Democratic Republic of the Congo. 

    ° On 16 May, a laboratory confirmed case has also been reported in Kinshasa, the Democratic Republic of the Congo, among someone returning from Ituri.

    ° Unusual clusters of community deaths with symptoms compatible with Bundibugyo virus disease (BVD) have been reported across several health zones in Ituri, and suspected cases have been reported across Ituri and North Kivu

    ° In addition, at least four deaths among healthcare workers in a clinical context suggestive of viral haemorrhagic fever have been reported from the affected area raising concerns regarding healthcare-associated transmission, gaps in infection prevention and control measures, and the potential for amplification within health facilities.

    ° There are significant uncertainties to the true number of infected persons and geographic spread associated with this event at the present time. In addition, there is limited understanding of the epidemiological links with known or suspected cases.

    ° However, the high positivity rate of the initial samples collected (with eight positives among 13 samples collected in various areas), the confirmation of cases in both Kampala and Kinshasa, the increasing trends in syndromic reporting of suspected cases and clusters of deaths across the province of Ituri all point towards a potentially much larger outbreak than what is currently being detected and reported, with significant local and regional risk of spread. 

    ° Moreover, the ongoing insecurity, humanitarian crisis, high population mobility, the urban or semi-urban nature of the current hotspot and the large network of informal healthcare facilities further compound the risk of spread, as was witnessed during the large Ebola virus disease epidemic in North Kivu and Ituri provinces in 2018-19. 

    ° However, unlike for Ebola-zaire strains, there are currently no approved Bundibugyo virus-specific therapeutics or vaccines. As such, this event is considered extraordinary.


2. The event constitutes a public health risk to other States Parties through the international spread of disease

    ° International spread has already been documented, with two confirmed cases reported in Kampala, Uganda on 15 and 16 May following travel from the Democratic Republic of the Congo. 

    ° Both confirmed cases were admitted to intensive care units in Kampala. 

    ° Neighboring countries sharing land borders with the Democratic Republic of the Congo are considered at high risk for further spread due to population mobility, trade and travel linkages, and ongoing epidemiological uncertainty.


3. The event requires international coordination and cooperation to understand the extent of the outbreak

    ° to coordinate surveillance, prevention and response efforts, to scale up and strengthen operations and ensure ability to implement control measures.


    The Director-General of WHO, under the provisions of the IHR, will be convening an Emergency Committee, as soon as possible to advise, inter alia, on the proposed temporary recommendation for States Parties to respond to the event.

    The WHO advice is enumerated below and will be subject to further refinement as appropriate after having considered the advice from the Emergency Committee and issuing of Temporary Recommendations.


WHO advice

    For States Parties where the event is occurring (the Democratic Republic of the Congo and Uganda)


Coordination and high-level engagement

    ° Activate their national disaster/emergency management mechanisms and establish an emergency operation centre, under the authority of the Head of State and relevant government authority, to coordinate response activities across partners and sectors to ensure efficient and effective implementation and monitoring of comprehensive Bundibugyo virus disease control measures. 

    ° These measures must include enhanced surveillance including contact tracing, infection prevention and control (IPC), risk communication and community engagement, laboratory diagnostic testing, and case management. 

    ° Coordination and response mechanisms should be established at national level, as well as at subnational level in affected areas and at-risk areas.

    ° Should national capacities be overwhelmed, collaboration with partners should be enhanced to strengthen operations and ensure the ability to implement control measures in all affected and neighbouring areas.


Risk communication and community engagement

    ° Ensure that there is a large-scale and sustained effort to fully engage the community – through local, religious and traditional leaders and healers – so communities play a central role in case identification, contact tracing and risk education; the population should be made fully aware of the benefits of early treatment.

    ° Strengthen community awareness, engagement, and participation in particular to identify and address cultural norms and beliefs that serve as barriers to their full participation in the response, and integrate the response within the wider response required to address the needs of the population, particularly in contexts of the protracted humanitarian crisis in Eastern DRC.


Surveillance and laboratory 

    ° Strengthening surveillance and laboratory capacity across affected provinces and neighbouring provinces, through the establishment of 

        - (1) dedicated surveillance and response cells within affected health zones and across key at-risk neighbouring health zones, 

        - (2) enhanced community surveillance, particularly focused on community deaths, and 

        - (3) decentralized laboratory capacity for testing of Bundibugyo virus.


Infection prevention and control in health facilities and in the context of care

    ° Strengthen measures to prevent nosocomial infections, including systematic mapping of health facilities, triage, targeted IPC interventions and sustained monitoring and sustained supervision.

    ° Ensure healthcare workers receive adequate training on IPC, including the proper use of PPE, and that health facilities have appropriate equipment to ensure the safety and protection of their staff, their timely payment of salaries and, as appropriate, hazard pay


Patients’ referral pathway and access to safe and optimized intensive care

    ° Ensure that suspected cases can be safely transferred to specialized clinical units for their isolation and management in a human and patient-centred approach.

    ° Establish specialized treatment centers or units, located close to outbreak epicenter(s), with staff trained and equipped to implement optimized intensive supportive care.


Research and development of medical countermeasures

    ° Implement clinical trials to advance the development and use of candidate therapeutics and vaccine, supported by partners. 


Border health, travels and mass-gathering events

    ° Undertake cross-border screening and screening at main internal roads to ensure that no suspected case is missed and enhance the quality of screening through improved sharing of information with surveillance teams.

    ° There should be no international travel of Bundibugyo virus disease contacts or cases, unless the travel is part of an appropriate medical evacuation. 

    ° To minimize the risk of international spread of Bundibugyo virus disease:

        - confirmed cases should immediately be isolated and treated in a Bundibugyo virus disease Treatment Centre with no national or international travel until two Bundibugyo virus-specific diagnostic tests conducted at least 48 hours apart are negative;

        - contacts (which do not include properly protected health workers and laboratory staff who have had no unprotected exposure) should be monitored daily, with restricted national travel and no international travel until 21 days after exposure;

        - probable and suspect cases should immediately be isolated and their travel should be restricted in accordance with their classification as either a confirmed case or contact.

        - Implement exit screening of all persons at international airports, seaports and major land crossings, for unexplained febrile illness consistent with potential Bundibugyo virus disease. The exit screening should consist of, at a minimum, a questionnaire, a temperature measurement and, if there is a fever, an assessment of the risk that the fever is caused by Bundibugyo virus disease. Any person with an illness consistent with Bundibugyo virus disease should not be allowed to travel unless the travel is part of an appropriate medical evacuation.

        - Consider postponing mass gatherings until BVD transmission is interrupted.


Safe and dignified burials

    ° Ensure funerals and burials are conducted by well-trained personnel, with provision made for the presence of the family and cultural practices, and in accordance with national health regulations, to reduce the risk of Bundibugyo virus infection. 

    ° The cross-border movement of the human remains of deceased suspect, probable or confirmed Bundibugyo virus disease cases should be prohibited unless authorized in accordance with recognized international biosafety provisions.


Operations, supplies and logistics

    ° Strong supply pipeline needs to be established to ensure that sufficient medical and laboratory commodities and other critical items, especially personal protective equipment (PPE), are available to those who appropriately need them.

    ° For States Parties with land borders adjoining States Parties with documented Bundibugyo virus disease

        - Unaffected States Parties with land borders adjoining States Parties with documented Bundibugyo virus disease  transmission should urgently enhance their preparedness and readiness capacity, including active surveillance across health facilities with active zero reporting, enhancement of community surveillance for clusters of unexplained deaths; establish access to a qualified diagnostic laboratory; ensure that health workers are aware of and trained in appropriate IPC procedures; and establish rapid response teams with the capacity to investigate and manage BVD cases and their contacts.

    ° Dedicated coordination mechanisms should be in place at national and subnational level in all Unaffected States Parties with land borders adjoining States Parties with documented cases of Bundibugyo virus disease. 

    ° States should be prepared to detect, investigate, and manage Bundibugyo virus disease cases; this should include assured access to a qualified diagnostic laboratory for Bundibugyo virus disease, isolation and case management capacity and activation of rapid response teams.

    ° Any State Parties newly detecting a suspected or confirmed Bundibugyo virus disease case or contact, or clusters of unexplained deaths should treat this as a health emergency, take immediate steps in the first 24 hours to investigate and stop a potential outbreak by instituting case isolation, case management, establishing a definitive diagnosis, and undertaking contact tracing and monitoring as required.

    ° If Bundibugyo virus disease is confirmed to be occurring in the State Party, the full recommendations for State Parties with Bundibugyo virus disease transmission should be implemented, on either a national or subnational level, depending on the epidemiologic and risk context. State Parties should immediately report the confirmation of Bundibugyo virus disease to WHO.

    ° Risk communications and community engagement, especially at points of entry, should be increased.

    ° At-risk countries should put in place approvals for investigational therapeutics as an immediate priority for preparedness.


For all Other States Parties

    ° No country should close its borders or place any restrictions on travel and trade. 

    ° Such measures are usually implemented out of fear and have no basis in science. 

    ° They push the movement of people and goods to informal border crossings that are not monitored, thus increasing the chances of the spread of disease. 

    ° Most critically, these restrictions can also compromise local economies and negatively affect response operations from a security and logistics perspective.

    ° National authorities should work with airlines and other transport and tourism industries to ensure that they do not exceed WHO’s advice on international traffic.

    ° States Parties should provide travelers to Bundibugyo virus disease affected and at-risk areas with relevant information on risks, measures to minimize those risks, and advice for managing a potential exposure.

    ° The general public should be provided with accurate and relevant information on the Bundibugyo virus disease outbreak and measures to reduce the risk of exposure.

    ° State Parties should be prepared to facilitate the evacuation and repatriation of nationals (e.g. health workers) who have been exposed to Bundibugyo virus disease.

    ° Entry screening at airports or other ports of entry outside the affected region are not considered needed for passengers returning from areas at risk.

Source: 


Link: https://www.who.int/news/item/17-05-2026-epidemic-of-ebola-disease-in-the-democratic-republic-of-the-congo-and-uganda-determined-a-public-health-emergency-of-international-concern

____

Saturday, May 16, 2026

Media #update on #Andes #hantavirus situation (Public Health Agency Canada, May 16 '26): one new case confirmed

 


Statement | May 16, 2026 | Ottawa, ON


    On May 16, 2026, the British Columbia Provincial Health Officer reported that one of the four high risk individuals who was self-isolating and being monitored for symptoms has tested presumptive positive for Andes hantavirus

    The person was transported to hospital for assessment and care on May 14 along with their spouse who also has mild symptoms

    The couple were passengers on the MV Hondius

    Both will remain in isolation in hospital. 

    Out of an abundance of caution, a third individual who was in secure lodging for isolation has been transferred to hospital for assessment and testing.

    All infection prevention and control protocols are being followed, including the use of personal protective equipment by healthcare workers and personnel involved in the repatriation. 

    Those involved in the repatriation are not considered at risk given the public health protective measures that were in place, in addition to the length of time between repatriation and the onset of symptoms.

    Samples have arrived at the Public Health Agency of Canada’s National Microbiology Laboratory (NML) in Winnipeg for confirmatory testing. Results are expected in the next two days.

    The Public Health Agency of Canada, the province of British Columbia, and local public health are working together to ensure all public health measures continue to be followed to protect the health of Canadians.

    The overall risk to the general population in Canada from the Andes hantavirus outbreak linked to the MV Hondius cruise ship remains low at this time

    But, given the severity of this virus, we are taking a precautionary approach to ensure Canadians are protected.

    The Public Health Agency of Canada will continue to actively monitor the situation, provide guidance and support to provincial/territorial public health partners and share updates as needed.


Contacts: Media Relations, Public Health Agency of Canada, 613-957-2983, media@hc-sc.gc.ca

Source: 


Link: https://www.canada.ca/en/public-health/news/2026/05/media-update-on-andes-hantavirus-situation0.html

____

#UK Health Security Agency #update on the #hantavirus #outbreak (May 16 '26)

 


Latest update

    The UK government continues to work with the NHS, local authorities and UK Overseas Territories in response to the hantavirus outbreak

    UKHSA and NHS staff have been closely monitoring those currently at Arrowe Park and those isolating at home to provide them with all necessary support. 

    A further individual has left Arrowe Park today to complete their 45-day isolation period at home after a clinical and public health assessment confirmed it was safe for them to do so.

    A contact from Ascension Island, a medic who developed symptoms, has now safely arrived at the High Consequence Infectious Disease (HCID) unit in Guy’s and St Thomas’ NHS Foundation Trust

    They were medically evacuated to the UK separately for specialist assessment, as a highly precautionary measure.

    While the individual is not a confirmed case, cases of Hantavirus can rapidly become very unwell and require critical care. 

    As there is no specialist infectious diseases unit on Ascension Island, the decision was made to bring them to the UK to ensure they receive the best possible support at a HCID unit should they become unwell. 

    The individual will undergo further testing and assessment at the unit today.

    As updated previously, UKHSA is working closely with FCDO and UK Overseas Territories to support the relocation of 9 asymptomatic contacts from St Helena and Ascension Island

    They will be brought to the UK to complete their self-isolation as a highly precautionary measure. 

    This will ensure they can be provided with the best possible support from the NHS’s HCID network should they become unwell.

    They are expected to arrive in the UK on Sunday and will be transferred to Arrowe Park where they will be closely monitored and offered all necessary support. The chartered flight will operate under strict infection prevention and control measures and medical checks will be carried out before the flight to ensure passengers are asymptomatic.

    Dr William Welfare, Director Health Protection in Regions at UKHSA, said:

    ''We would like to thank those who remain in isolation at Arrowe Park, as well as those now self-isolating at home. We know how difficult and stressful a time this continues to be for all those involved and we are very grateful for their cooperation.

    ''Our teams will continue to work closely with all those affected by this outbreak, ensuring everyone has the necessary support in place.

    ''I am very pleased to hear the contact who developed symptoms on Ascension Island is now safely being cared for at the High Consequence Infectious Diseases unit in Guy’s and St Thomas’ NHS Foundation Trust.

    ''UKHSA continues to work closely with FCDO, DHSC and NHS colleagues to safely bring the British nationals currently isolating on St Helena and Ascension Island to the UK.

    ''The risk to the general public remains very low.

    Further information on the rapid response mobile laboratory can be found in the recent blog from UKHSA.

Source: 


Link: https://www.gov.uk/government/news/ukhsa-update-on-the-hantavirus-cruise-ship-outbreak

____

Imported case of avian #influenza #H9N2 virus #infection in a patient with miliary #tuberculosis, #Italy, March 2026

 


Abstract

On 21 March 2026, avian influenza A(H9N2) virus was confirmed in Italy in a patient with miliary tuberculosis. The patient had recently travelled to West Africa. Following the detection of an unsubtypable influenza A virus, rapid molecular confirmation and full genome sequencing were performed. Phylogenetic analysis revealed that the virus belonged to subclade G5.5 and was closely related to African strains. Epidemiological investigations identified no additional cases, suggesting there was no evidence of onward transmission at the time of reporting.

Source: 


Link: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.15.2600285#abstract_content

____

#Statement on the #antigen #composition of #COVID19 #vaccines (#WHO, May 16 '26)

 


Key points:

    -- The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) held its twice-yearly decision-making meeting in May 2026 to review the evolution of SARS-CoV-2, the effectiveness of currently approved COVID-19 vaccines and the implications for COVID-19 vaccine antigen composition.

    -- The objective of any update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants, when needed.

    -- Following this meeting, the TAG-CO-VAC advises vaccine manufacturers that monovalent LP.8.1 is the recommended vaccine antigen.

    -- Other antigens (e.g. XFG, NB.1.8.1) or other approaches that demonstrate broad and robust neutralizing antibody responses or efficacy against currently circulating SARS-CoV-2 variants could also be used.

    -- Vaccination remains an important public health countermeasure against COVID-19 and vaccination should not be delayed in anticipation of access to vaccines with an updated antigen composition. As per the March 2026 WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommendations, Member States should consider routine COVID-19 vaccination of groups at highest risk of severe COVID-19 disease.


    -- The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to closely monitor the genetic and antigenic evolution of SARS-CoV-2 variants, immune responses to SARS-CoV-2 infection and COVID-19 vaccination, and the effectiveness of COVID-19 vaccines against circulating variants. 

    -- Based on these evaluations, WHO advises vaccine manufacturers and regulatory authorities on the implications for future updates to COVID-19 vaccine antigen composition. 

    -- In December 2025, the TAG-CO-VAC advised vaccine manufacturers that monovalent LP.8.1 is the recommended vaccine antigen. Multiple manufacturers (using mRNA or recombinant protein-based vaccines) have updated COVID-19 vaccine antigen composition to monovalent LP.8.1 formulation. Several of these vaccines have been approved for use by regulatory authorities and have been introduced into vaccination programmes. Previous statements from the TAG-CO-VAC can be found on the WHO website.

    -- The TAG-CO-VAC reconvened on 7-8 May 2026 to review the genetic and antigenic evolution of SARS-CoV-2; immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination; the effectiveness of currently approved vaccines against circulating SARS-CoV-2 variants; and the implications for COVID-19 vaccine antigen composition.


Evidence reviewed

    -- The published and unpublished evidence reviewed by the TAG-CO-VAC included: 

    (1) SARS-CoV-2 genetic evolution, with additional support from the WHO Technical Advisory Group on Virus Evolution (TAG-VE); 

    (2) Antigenic characterization of previous and emerging SARS-CoV-2 variants using virus neutralization tests with animal antisera and further analysis of antigenic relationships using antigenic cartography; 

    (3) Immunogenicity data on the breadth of neutralizing antibody responses elicited by currently approved vaccine antigens against circulating SARS-CoV-2 variants using animal and human sera, with additional support from WHO Coronavirus Network (CoViNet); 

    (4) Preliminary clinical immunogenicity data on immune responses following infection with circulating SARS-CoV-2 variants; 

    (5) Available COVID-19 vaccine effectiveness (VE) estimates of currently approved vaccines; and 

    (6) Preliminary non-clinical and clinical immunogenicity data on the performance of candidate vaccines with updated antigens shared by vaccine manufacturers with TAG-CO-VAC. 

    Further details on the data reviewed by the TAG-CO-VAC can be found in the accompanying data annex. Confidential data reviewed by the TAG-CO-VAC are not shown.


Summary of available evidence

    There are persistent and increasing gaps and delays in the surveillance and reporting of cases, hospitalizations and deaths from WHO Member States, limiting the interpretation and comparability of epidemiological trends over time. 

    In 2026, SARS-CoV-2 continues to circulate globally, causing severe disease, post COVID-19 condition, and death. 

    However, the impact on health systems has reduced substantially compared to 2020-2021 due to multiple factors, including increased population immunity from infection and/or vaccination and improved clinical management. 

    In 2026, all WHO regions are reporting lower SARS-CoV-2 test positivity rates than during the corresponding period in previous years.

    Globally, the current predominant variant among SARS-CoV-2 sequences remains Variant Under Monitoring (VUM) XFG, however the weekly proportion is now declining. 

    In contrast, in countries in the WHO Western Pacific Region where sequencing continues, VUM NB.1.8.1 is the predominant variant

    Globally, the proportion of VUM BA.3.2 is increasing, with heterogeneous dynamics across countries where genomic surveillance continues. 

    BA.3.2 appears to have lower fitness than JN.1-descendant variants, which may explain why BA.3.2 has not displaced JN.1-descendant variants in regions where it has been detected. 

    To date, the increase in the proportion of BA.3.2 does not appear to be associated with a substantial increase in disease burden, unlike increases associated with previous Variants of Interest and JN.1-descendant variants. 

    In several countries, BA.3.2 appears to account for a higher proportion of sequences from young children than adults, suggesting possible differences in susceptibility to BA.3.2 related to a lack of cross-reactive immunity generated by previous exposure to early SARS-CoV-2 variants. 

    However, sequence numbers and the reported number of infected individuals, including those with severe disease, remain low; this observation should therefore be interpreted with caution.

    Neutralization data using antisera from naĂ¯ve animals infected or vaccinated with JN.1, LP.8.1, NB.1.8.1 or XFG, indicated that recent JN.1-descendant variants are antigenically closely related

    These variants differed by approximately 1 antigenic unit in cartographic analyses, corresponding to a two-fold-difference in neutralization, with XFG often the most antigenically distant from JN.1 within the JN.1 cluster. 

    In contrast, these antisera showed limited neutralizing activity against BA.3.2

    Antisera from naĂ¯ve animals infected with BA.3.2 showed very limited cross-reactivity with recent JN.1-descendant variants. 

    Together, these results indicate that BA.3.2 is antigenically distinct from JN.1- descendant variants.

    Sera from cohorts that are representative of recent population immunity and pre-LP.8.1 vaccination sera demonstrated cross-reactivity with recent JN.1-descendant variants and with BA.3.2.

    Pre- and post-vaccination sera from individuals immunized with LP.8.1 demonstrated significant increases in neutralizing activity against JN.1 and its descendant variants, including NB.1.8.1 and XFG. 

    Post-vaccination neutralizing antibody titers and the fold change against BA.3.2 were lower than against the homologous LP.8.1 antigen and other JN.1- descendant variants.

    Pre- and post-vaccination sera from individuals immunized with JN.1 or KP.2 demonstrated significant increases in neutralizing activity against JN.1 and its descendant variants. 

    However, post-vaccination neutralizing antibody titers against NB.1.8.1 and XFG were lower than those against the homologous JN.1 or KP.2 antigens, with even larger reductions typically observed for BA.3.2.

    Contemporary vaccine effectiveness (VE) estimates are relative (rVE) and demonstrate the added or incremental protection of recent vaccination over and above pre-existing infection- and vaccine-derived immunity. 

    Monovalent JN.1 and KP.2 mRNA vaccines demonstrated additional protection—relative to pre-existing immunity—against symptomatic and severe COVID-19. 

    The limited number of rVE estimates using monovalent LP.8.1 vaccines also demonstrated additional protection against symptomatic and severe COVID-19.

    Data shared with the TAG-CO-VAC by vaccine manufacturers showed that:

      - Immunization of naĂ¯ve mice with monovalent LP.8.1, XFG or NB.1.8.1 induced high neutralizing antibody titers against the homologous antigen, as well as other JN.1-descendant variants. 

    - Low or non-detectable neutralizing antibody titers were consistently observed against BA.3.2

    - In contrast, immunization of naĂ¯ve mice with monovalent BA.3.2 induced immune responses largely restricted to the homologous antigen. 

    - Overall immunogenicity of BA.3.2 was lower than after LP.8.1, XFG or NB.1.8.1 immunization.

    - Immunization of mice previously immunized with SARS-CoV-2 variants and then immunized with LP.8.1, XFG or NB.1.8.1 induced high neutralizing antibody titers against JN.1-descendant variants. 

    - Lower neutralizing antibody titers against BA.3.2 were observed. 

    - Immunization with BA.3.2 induced neutralizing titers against the homologous antigen, and to a lesser extent against JN.1-descedant variants. 

    - However, overall immunogenicity of BA.3.2 was lower than after LP.8.1, XFG or NB.1.8.1 immunization.

    - In humans, vaccination with 8.1 induced strong increases in neutralizing antibody titers against JN.1, LP.8.1, NB.1.8.1 and XFG. 

    - As in mice, post- vaccination neutralizing antibody titers against BA.3.2 were lower than those against the homologous LP.8.1 antigen. 

    - A single clinical immunogenicity study using a BA.3.2 vaccine candidate showed increased neutralizing antibody titers against the homologous antigen, and a back boost against JN.1-descendant variants, but overall lower immunogenicity than the LP.8.1 vaccine.

    - Overall, LP.8.1 as a vaccine antigen in populations with high levels of prior infection and / or vaccination continues to induce broadly cross-reactive immune responses to circulating SARS-CoV-2 variants.


    -- The TAG-CO-VAC acknowledges several limitations of available data:

    - There are persistent and increasing gaps and delays in the reporting of cases, hospitalizations and deaths, from WHO Member States, as well as in genetic/genomic surveillance of SARS-CoV-2 globally, including low numbers of samples sequenced and limited geographic diversity. The TAG-CO-VAC strongly supports the ongoing work of the WHO Coronavirus Network (CoViNet) and the Global Influenza Surveillance and Response System (GISRS) to address this information gap.

    - The timing, specific mutations and antigenic characteristics of emerging and future variants are difficult to predict, and the potential public health impact of these variants remain unknown. Currently, two antigenically distinct lineages (JN.1-descendant and BA.3.2-descendant variants) are circulating and the comparative evolutionary potential of these lineages remains uncertain. Variants derived from these lineages will continue to be monitored and/or characterized, and the TAG-CO-VAC strongly supports the ongoing work of the TAG-VE. 

    - Although neutralizing antibody titers have been shown to be important correlates of protection from SARS-CoV-2 infection and of estimates of vaccine effectiveness, there are multiple components of immune protection elicited by infection and/or vaccination. Data on the immune responses following JN.1-descendant variant infection or monovalent LP.8.1 vaccination are largely restricted to neutralizing antibodies. Data and interpretation of other aspects of the immune response, including cellular immunity, are limited. 

    - Immunogenicity data against currently circulating SARS-CoV-2 variants are not available for all COVID-19 vaccines. 

    - Recent estimates of rVE are limited in terms of the number of studies, geographic diversity, vaccine platforms evaluated, populations assessed, duration of follow-up, and contemporary comparisons of vaccines with different antigen composition. There are currently only a limited number of available rVE estimates using monovalent LP.8.1 mRNA vaccines; there are no rVE estimates in populations in which BA.3.2 was the predominant variant.


Recommendations for COVID-19 vaccine antigen composition

    -- Monovalent LP.8.1 (Nextstrain: 25A; GenBank: PV074550.1; GISAID: EPI_ISL_19467828) is the recommended COVID-19 vaccine antigen.

    -- Other antigens (e.g. XFG, NB.1.8.1) or other approaches that demonstrate broad and robust neutralizing antibody responses or efficacy against currently circulating SARS-CoV-2 variants could also be used.

    -- As per the March 2026 WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommendations, Member States should consider routine COVID-19 vaccination of groups at highest risk of severe COVID-19 disease and vaccination should not be delayed in anticipation of access to vaccines with an updated antigen composition.


Further data requested

    -- Given the limitations of the evidence upon which the recommendations above are derived and the anticipated continued evolution of the virus, the TAG-CO-VAC strongly encourages generation of the following data (in addition to the types of data outlined in March 2026)

    - Immune responses and clinical endpoints (i.e. VE and/or comparator rates of infection and severe disease) in varied human populations who receive currently approved COVID-19 vaccines against emerging SARS-CoV-2 variants, across different vaccine platforms.

    - Strengthened epidemiological and virological surveillance, as per the Standing Recommendations for COVID-19 in accordance with the International Health Regulations (2005), to determine if emerging variants are antigenically distinct and able to displace circulating variants.

    - Strengthened epidemiological surveillance to characterize disease severity in immunologically naĂ¯ve and/ or immature individuals (e.g. young pediatric cohorts), particularly for BA.3.2 infections.

    - Non-clinical and clinical immunogenicity data against circulating SARS-CoV-2 variants for vaccine candidates with different SARS-CoV-2 antigens.

    - As previously stated, the TAG-CO-VAC continues to encourage the further development of vaccines that may improve protection against infection and reduce transmission of SARS-CoV-2.

    -- The TAG-CO-VAC will continue to closely monitor the genetic and antigenic evolution of SARS-CoV-2 variants, immune responses to SARS-CoV-2 infection and COVID-19 vaccination, and the effectiveness of COVID-19 vaccines against circulating variants. The TAG-CO-VAC will also continue to reconvene every six months, or as needed, to evaluate the implications for COVID-19 vaccine antigen composition. At each meeting, recommendations to either maintain current vaccine composition or to consider updates will be issued. Prior to each meeting, the TAG-CO-VAC will publish an update to the statement on the types of data requested to inform COVID-19 vaccine antigen composition deliberations.

Source: 


Link: https://www.who.int/news/item/16-05-2026-statement-on-the-antigen-composition-of-covid-19-vaccines

____

#Andes #hantavirus #outbreak #Update: 16 May 2026 (ECDC, edited): No New Cases since last update

 


    ECDC was notified on 2 May 2026 of a cluster of severe respiratory illness on MV Hondius, a Dutch-flagged cruise ship with passengers and crew from 23 countries, including nine EU/EEA countries. 

    The virus has been identified as Andes hantavirus.

    As of 16 May, a total of eleven cases have been reported, including eight confirmed, two probable, and one inconclusive

    No new cases or deaths have been reported since the previous update

    The risk to the EU/EEA general population remains very low.

___

    -- Confirmed cases***: 8

    -- Probable cases**: 2

    -- Suspected cases*: 0

    -- Inconclusive cases****: 1

    -- Number of deaths3

___

Notes

    {*} A suspected case is a person who has been on or visited the same transport (e.g. ship or plane) where a confirmed or probable Andes hantavirus (ANDV) case was present, 

    - OR - 

    - has been in contact with a passenger or crew member of the MV Hondius since 5 April, 

    - AND -

    - has a fever (currently or recently), plus at least one of the following symptoms: 

        ° muscle aches

        ° chills

        ° headache

        ° stomach problems (such as nausea, vomiting, diarrhoea, or abdominal pain)

        ° breathing problems (such as cough, shortness of breath, chest pain, or difficulty breathing)


    {**} A probable case is a person who has the symptoms listed above, and is known to have been in contact with a confirmed or probable ANDV case


    {***} A confirmed case is a person who meets the suspected or probable case definition, and has a laboratory test that confirms ANDV infection (PCR or antibody test)


    {****} An inconclusive case means awaiting further laboratory investigations.


    Non-case: A non-case is a person who was initially considered a suspected or probable case, but tests negative for ANDV using laboratory tests (PCR or antibody test).

Source: 


Link: https://www.ecdc.europa.eu/en/infectious-disease-topics/hantavirus-infection/surveillance-and-updates/andes-hantavirus-outbreak

____

History of Mass Transportation: Transferoviar Multiple Unit, formerly DB class 624 seen at București Nord on 4 November 2014

 


{Click on Image to Enlarge}

By Phil Richards from London, UK - 04.11.14 București Nord 76.2406, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=37108856

Source: 


Link: https://en.wikipedia.org/wiki/Rolling_stock_of_the_Romanian_Railways

____

____

#Coronavirus Disease Research #References (AMEDEO, May 16 '26)

 


    Ann Intern Med

  1. JOHNSON D, Quinn S, Algase LF, Watkins C Jr, et al
    Telemedicine Policy and Practice: A Position Paper From the American College of Physicians.
    Ann Intern Med. 2026 May 12. doi: 10.7326/ANNALS-25-04194.
    PubMed         Abstract available


    BMJ

  2. SUMMERS C, Cook T, Suntharalingam G, Fong K, et al
    Covid Inquiry module 3 reveals critical gaps in UK health system resilience.
    BMJ. 2026;393:s846.
    PubMed        


    Br J Anaesth

  3. FRASER S, Syratt T, Bridson JD, Gilbert-Kawai N, et al
    Refusal of blood transfusion based on donor COVID-19 vaccination status: an emerging postpandemic challenge for perioperative care.
    Br J Anaesth. 2026 May 13:S0007-0912(26)00279-5. doi: 10.1016/j.bja.2026.
    PubMed        


    Clin Infect Dis

  4. PEREZ MA, Patel KA, Rasmy L, Yoshida H, et al
    Changes in Epidemiology of Candidemia in the United States with a Focus on Candida auris.
    Clin Infect Dis. 2026 May 11:ciag312. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  5. MENG L, Bell JM, Barbre K, Guthrie S, et al
    Using a longitudinal k-means clustering method to explore nursing home factors associated with SARS-CoV-2 infection peak and resilience to a COVID-19 surge.
    Infect Control Hosp Epidemiol. 2026 May 14:1-7. doi: 10.1017/ice.2026.10406.
    PubMed         Abstract available


    Int J Infect Dis

  6. KIM S, Chun BC
    Heterogeneous Rebound Patterns of Foodborne Diseases after COVID-19 Non-Pharmaceutical Interventions, South Korea, 2005-2024.
    Int J Infect Dis. 2026 May 13:108782. doi: 10.1016/j.ijid.2026.108782.
    PubMed         Abstract available

  7. WENG TP, Li MC, Tsai HP, Chen CJ, et al
    Viral Rebound and Clinical Outcomes in Hospitalized Patients with COVID-19.
    Int J Infect Dis. 2026 May 13:108796. doi: 10.1016/j.ijid.2026.108796.
    PubMed         Abstract available

  8. SHI R, Li Y, Liu L, Wang Y, et al
    Molecular epidemiology and genomic characterization of post-pandemic macrolide-resistant Mycoplasma pneumoniae in hospitalized children.
    Int J Infect Dis. 2026 May 13:108780. doi: 10.1016/j.ijid.2026.108780.
    PubMed         Abstract available

  9. MARTINEZ-DIAZ I, Nunez-Delgado S, Ortiz-Perez JT, Morales A, et al
    Increased circulating ACE2 and GAS6 are independent predictors of COVID-19 severity.
    Int J Infect Dis. 2026 May 12:108775. doi: 10.1016/j.ijid.2026.108775.
    PubMed         Abstract available

  10. HEYMER EJ, Campbell H, Clark SA, Lucidarme J, et al
    Lower incidence and higher case fatality rates associated with invasive meningococcal disease during COVID-19 pandemic restrictions (March 2020 to July 2021) in England.
    Int J Infect Dis. 2026 May 10:108770. doi: 10.1016/j.ijid.2026.108770.
    PubMed         Abstract available

  11. NIAMSANIT S, Sitthikarnkha P, Techasatian L, Saengnipanthkul S, et al
    Incidence Trends, Outcomes, and Factors Associated with Mortality in Multisystem Inflammatory Syndrome in Children: A Nationwide Study in Thailand during 2021-2023.
    Int J Infect Dis. 2026 May 6:108766. doi: 10.1016/j.ijid.2026.108766.
    PubMed         Abstract available


    J Med Virol

  12. YAVUZ HC, Boysan SN, Tuna MM
    FIB-4 Index and APRI Score Predict Short- and Long-Term Mortality in Hospitalized COVID-19 Patients: A 4-Year Follow-Up Study.
    J Med Virol. 2026;98:e70964.
    PubMed         Abstract available

  13. KIM DS, Kim U, Woo HM, Lee H, et al
    Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus-2.
    J Med Virol. 2026;98:e70969.
    PubMed         Abstract available


    J Virol

  14. MCCABE M, Groves HE, Getty E, Campbell E, et al
    Age-dependent expression and antiviral activity of interferon epsilon in respiratory epithelium.
    J Virol. 2026 May 12:e0057825. doi: 10.1128/jvi.00578.
    PubMed         Abstract available

  15. LI P, Zheng Y-M, Liu S-L
    Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.
    J Virol. 2026 May 12:e0001626. doi: 10.1128/jvi.00016.
    PubMed         Abstract available


    Lancet Infect Dis

  16. HANSEN CH, Soborg B, Rasmussen M, Moustsen-Helms IR, et al
    Effectiveness of the BNT162b2 LP.8.1-adapted SARS-CoV-2 vaccine against COVID-19-associated hospitalisation and death: a Danish nationwide cohort study.
    Lancet Infect Dis. 2026 May 13:S1473-3099(26)00236.
    PubMed        


    N Engl J Med

  17. HAYDEN FG, Shinkai M, Clark TW, Luetkemeyer AF, et al
    Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
    N Engl J Med. 2026;394:1905-1915.
    PubMed         Abstract available


    Nature

  18. DOLGIN E
    At last, a pill that can prevent COVID after exposure to infected people.
    Nature. 2026 May 13. doi: 10.1038/d41586-026-01546.
    PubMed        


    Science

  19. LESSLER J, Christensen A
    From wastewater analysis to public health action.
    Science. 2026;392:692.
    PubMed         Abstract available

  20. HILL DT, Schulman R, Caldas IV, Dunham C, et al
    Genetic variability of SARS-CoV-2 in wastewater and associations with community transmission.
    Science. 2026;392:735-741.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 16 '26)

 


    Antiviral Res

  1. PANG L, Zou J, Yuan Z, Zhao P, et al
    Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity.
    Antiviral Res. 2026;250:106417.
    PubMed         Abstract available


    Cell

  2. QIAN W, Wei X, Barros AJ, Ye X, et al
    Respiratory viral infections prime accelerated lung cancer growth.
    Cell. 2026;189:2845-2856.
    PubMed         Abstract available


    Drug Saf

  3. SHETTY AN, Mallard JH, Hennessy D, Wood N, et al
    Giant Cell Arteritis Following COVID-19 Vaccination: A Consumer-Stimulated Analysis.
    Drug Saf. 2026;49:705-715.
    PubMed         Abstract available


    J Clin Microbiol

  4. SMITH ZR, Godoshian A, Boersma P, Myrick C, et al
    Evaluation of self-collection of nasal swab specimens for COVID-19 diagnostic testing in children in the United States, 2020-2023.
    J Clin Microbiol. 2026;64:e0133625.
    PubMed         Abstract available


    J Gen Virol

  5. BHAT S, Sadeyen JR, Yang J, Chrzastek K, et al
    A G57 (BJ/94-like) H9N2 avian influenza virus exhibits enhanced replication and tissue dissemination in chickens compared with a G1-B virus.
    J Gen Virol. 2026;107.
    PubMed         Abstract available


    J Infect Dis

  6. COLDBECK-SHACKLEY RC, Flynn E, Mudhar AK, Taouk ML, et al
    Increased Diversity and Introduction of Multidrug-Resistant Strains of Neisseria gonorrhoeae Following Cessation of COVID-19 Pandemic-Related Travel Restrictions: An Observational Genomic Epidemiologic Study.
    J Infect Dis. 2026;233:e1130-e1140.
    PubMed         Abstract available

  7. LUCENA LAGE S, Rocco JM, Oguz C, Otaizo-Carrasquero F, et al
    Inflammasome Activation and Oxidative Stress in SARS-CoV-2 Infection and Symptomatic Rebound.
    J Infect Dis. 2026;233:e1285-e1297.
    PubMed         Abstract available

  8. BOECKH M, Xie H, Stevens-Ayers T, Sircy L, et al
    Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.
    J Infect Dis. 2025 Dec 31:jiaf649. doi: 10.1093.
    PubMed         Abstract available

  9. ZHANG R, Shang X, Wang C, Zhou H, et al
    Rhinovirus-Associated Lower Respiratory Tract Infection in Hospitalized Adult Patients: A Retrospective Cohort Study.
    J Infect Dis. 2026;233:868-876.
    PubMed         Abstract available


    J Virol

  10. XU C, Peng Y, Liu S, Xie R, et al
    Cellular hnRNP D promotes influenza A virus replication by inhibiting TBK1-IRF3-mediated innate immune response.
    J Virol. 2026 May 13:e0025726. doi: 10.1128/jvi.00257.
    PubMed         Abstract available

  11. CHEN X, Zheng X, Zhang L, Cai X, et al
    Long noncoding RNA#61 synergizes with viral PA-X to augment pyroptosis and attenuate the virulence of highly pathogenic H5N1 influenza virus in mice.
    J Virol. 2026 May 12:e0221425. doi: 10.1128/jvi.02214.
    PubMed         Abstract available

  12. VAN PUL L, Rosendahl Huber SK, Jacobi R, Hendriks M, et al
    Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.
    J Virol. 2026 May 12:e0040726. doi: 10.1128/jvi.00407.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  13. ROLFES MA, Bauck L, Lipton BA, Margrey SF, et al
    Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks - United States, July-December 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:234-239.
    PubMed         Abstract available

  14. ROLFES MA, Bauck L, Lipton BA, Margrey SF, et al
    Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks - United States, July-December 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:234-239.
    PubMed         Abstract available


    N Engl J Med

  15. HAYDEN FG, Shinkai M, Clark TW, Luetkemeyer AF, et al
    Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
    N Engl J Med. 2026;394:1905-1915.
    PubMed         Abstract available


    PLoS Comput Biol

  16. KIERAN TJ, Maines TR, Belser JA
    Limited 'heft' of weight-based outcomes in predicting influenza A virus disease severity in ferrets.
    PLoS Comput Biol. 2026;22:e1014210.
    PubMed         Abstract available

  17. YU G, Garee M, Ventresca M, Yih Y, et al
    Modeling individual self-protective behavior during epidemics.
    PLoS Comput Biol. 2026;22:e1014252.
    PubMed         Abstract available


    PLoS Med

  18. GOODFELLOW L, Quilty BJ, van Zandvoort K, Edmunds WJ, et al
    Social contact patterns in the United Kingdom following the COVID-19 pandemic: The Reconnect cross-sectional survey.
    PLoS Med. 2026;23:e1005038.
    PubMed         Abstract available


    PLoS One

  19. ZOUGHEIB Y, Salameh N, Slim A, Wehbi Z, et al
    Effect of screen time and outdoor activities on myopia progression.
    PLoS One. 2026;21:e0347118.
    PubMed         Abstract available

  20. YEHIA N, Ibrahim M, Shady RM, Mohamed AAE, et al
    Concurrent circulation of avian influenza viruses H5N1 and H9N2 enhances the genetic evolution of reassortant viruses in Egyptian poultry populations.
    PLoS One. 2026;21:e0348609.
    PubMed         Abstract available

  21. CANTON L, Schalkwijk P, Landier J, Rebaudet S, et al
    Socioeconomic inequalities and the COVID-19 pandemic in France: Territorial analyzes based on epidemic wave and metropolitan area.
    PLoS One. 2026;21:e0348201.
    PubMed         Abstract available

  22. SUGIYAMA A, Takafuta T, Abe K, Yoshinaga Y, et al
    Differences in the long-term course of post-COVID-19 symptoms in adults and children across epidemic periods: A retrospective cohort study in Japan, 2020-2024.
    PLoS One. 2026;21:e0348954.
    PubMed         Abstract available

  23. HUGHES A, Barnard S, Bauer-Staeb C, Holleyman R, et al
    Life lost due to the COVID-19 pandemic: A model-based cohort analysis of mortality displacement in the registered population of England.
    PLoS One. 2026;21:e0348575.
    PubMed         Abstract available

  24. LIU Y, Lu E, Ellingson KD, Hollister J, et al
    Unveiling post-vaccination proteomic signatures in SARS-CoV-2 infection-naive individuals associated with Omicron breakthrough infections.
    PLoS One. 2026;21:e0347602.
    PubMed         Abstract available

  25. FREITAS EL, Erbisti RS, Grinberg-Weller B, Pinto DCC, et al
    Spatiotemporal analysis of psychoactive drug consumption in Brazil during the COVID-19 pandemic.
    PLoS One. 2026;21:e0343552.
    PubMed         Abstract available

  26. TOGEL J, Kuhbandner C
    Fear and the internalization of external regulation - An exploratory study on how fear of COVID-19 affected the internalization of mask-wearing.
    PLoS One. 2026;21:e0347772.
    PubMed         Abstract available

  27. MILLER SL, Yan S, Garcia A, Wang LL, et al
    Potential airborne transmission of SARS-COV-2 through bathroom ventilation ducts associated with an outbreak in a residential building in Santander, Spain, 2020.
    PLoS One. 2026;21:e0345041.
    PubMed         Abstract available

  28. DOMINGUEZ-MONTERROZA A, Jimenez-Martin A, Mateos Caballero A
    Network geometry, topology, and spectral analysis in global stock markets: Insights from using the Ricci curvature, Euler characteristic, and random matrix theory.
    PLoS One. 2026;21:e0347767.
    PubMed         Abstract available

  29. BRAUN J, Kopp J, Kunzi L, Puhan MA, et al
    Measurement properties of the 30-second sit-to-stand test in post COVID-19 condition: Results from the PYCNOVID randomised controlled trial.
    PLoS One. 2026;21:e0348275.
    PubMed         Abstract available

  30. LAURENCE J, Smyth E
    COVID-19 pandemic stressors and their longer-term association with young people's wellbeing.
    PLoS One. 2026;21:e0347875.
    PubMed         Abstract available

  31. SCHERBOV S, Pothisiri W, Prasitsiriphon O, Ediev DM, et al
    Survival and life expectancy inequality by gender in Thai provinces: Trends from 2015 to 2023.
    PLoS One. 2026;21:e0348587.
    PubMed         Abstract available

  32. AZANERO-HARO J, Soto A
    Comparison of the performance of four clinical prediction rules for mortality in patients with COVID-19.
    PLoS One. 2026;21:e0348683.
    PubMed         Abstract available

  33. PENG Y
    Sustainability-induced loyalty in festival tourism: Examining the mediating pathways between sustainable practices and visitor behavioral support.
    PLoS One. 2026;21:e0348506.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  34. KEARNS FL, Bogetti AT, Calvo-Tusell C, Braza MKE, et al
    D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes.
    Proc Natl Acad Sci U S A. 2026;123:e2504793123.
    PubMed         Abstract available

  35. SIMKO T, Johnson RA
    Alleviating administrative burdens in rental assistance promotes access and program efficiency.
    Proc Natl Acad Sci U S A. 2026;123:e2512756123.
    PubMed         Abstract available


    Vaccine

  36. CARLOCK MA, Ross TM
    Retooling a novel influenza B hemagglutinin to redirect neutralizing antibodies against B/Victoria strains.
    Vaccine. 2026;84:128674.
    PubMed         Abstract available


    Virology

  37. WANG R, Chen J, Zhang H, Qin Y, et al
    Characterization of monoclonal antibody and identification of two novel linear epitopes on the hemagglutinin protein of H3N2 canine influenza virus.
    Virology. 2026;621:110923.
    PubMed         Abstract available

  38. DING K, Ding Y
    H5N1 avian influenza in dairy cattle: Molecular adaptation, transmission mechanisms, and control strategies.
    Virology. 2026;621:110927.
    PubMed         Abstract available

  39. ZHANG Y, Liu L, Chen T, Li M, et al
    CD25(+) cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice.
    Virology. 2026;621:110938.
    PubMed         Abstract available

My New Space

Most Popular Posts